Abstract

Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The < 100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.

Original languageEnglish (US)
Pages (from-to)563-601
Number of pages39
JournalProgress in Molecular Biology and Translational Science
Volume104
DOIs
StatePublished - 2011

Fingerprint

Nanoparticles
Nanomedicine
Pharmaceutical Preparations
Communicable Diseases
Regeneration
Cochlear Implants
Hematologic Diseases
Therapeutics
Phagocytes
Dendritic Cells
Cartilage
Monocytes
Lung Neoplasms
Anti-Inflammatory Agents
Central Nervous System
Joints
Macrophages
Technology
Skin
Antibodies

Keywords

  • Cell-based delivery
  • Human immunodeficiency virus
  • Macrophage
  • Mononuclear phagocyte
  • Nanomedicine
  • Nanoparticle
  • Nanotoxicology
  • Neurodegenerative disorders
  • Translational medicine

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Cell delivery of therapeutic nanoparticles. / McMillan, JoEllyn M; Batrakova, Elena; Gendelman, Howard Eliot.

In: Progress in Molecular Biology and Translational Science, Vol. 104, 2011, p. 563-601.

Research output: Contribution to journalArticle

@article{2a44929838934b1c81b5416c5d0bd792,
title = "Cell delivery of therapeutic nanoparticles",
abstract = "Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The < 100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.",
keywords = "Cell-based delivery, Human immunodeficiency virus, Macrophage, Mononuclear phagocyte, Nanomedicine, Nanoparticle, Nanotoxicology, Neurodegenerative disorders, Translational medicine",
author = "McMillan, {JoEllyn M} and Elena Batrakova and Gendelman, {Howard Eliot}",
year = "2011",
doi = "10.1016/B978-0-12-416020-0.00014-0",
language = "English (US)",
volume = "104",
pages = "563--601",
journal = "Progress in Molecular Biology and Translational Science",
issn = "1877-1173",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cell delivery of therapeutic nanoparticles

AU - McMillan, JoEllyn M

AU - Batrakova, Elena

AU - Gendelman, Howard Eliot

PY - 2011

Y1 - 2011

N2 - Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The < 100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.

AB - Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The < 100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.

KW - Cell-based delivery

KW - Human immunodeficiency virus

KW - Macrophage

KW - Mononuclear phagocyte

KW - Nanomedicine

KW - Nanoparticle

KW - Nanotoxicology

KW - Neurodegenerative disorders

KW - Translational medicine

UR - http://www.scopus.com/inward/record.url?scp=81255172965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255172965&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-416020-0.00014-0

DO - 10.1016/B978-0-12-416020-0.00014-0

M3 - Article

C2 - 22093229

AN - SCOPUS:81255172965

VL - 104

SP - 563

EP - 601

JO - Progress in Molecular Biology and Translational Science

JF - Progress in Molecular Biology and Translational Science

SN - 1877-1173

ER -